A discrete choice experiment (DCE) revealed no meaningful difference in preference between dual biologic therapy (DBT) or monotherapy among patients with inflammatory bowel disease (IBD) who had ...

Biologic therapies use parts from living organisms to target and interrupt inflammatory processes in the body. These medications may help people manage inflammation in Crohn’s disease. While ...

We have previously demonstrated that histological normalization in ulcerative colitis (UC) is associated with superior maintenance of remission outcomes. This single-center, retrospective case-control ...

Hyperbaric oxygen therapy was well tolerated in treatment-refractory ulcerative colitis and enhanced clinical outcomes alongside improved bowel perfusion.

Vedolizumab as a first-line biologic in UC offers cost savings and clinical benefits, improving QALYs compared to TNF-α inhibitors. In CD, vedolizumab provides incremental benefits but incurs higher ...

Most patients with inflammatory bowel disease (IBD) respond to initial therapy, but an estimated 10% to 40% don't, and some others become resistant to treatment over long periods of time. For many ...

Inflammatory bowel disease (IBD) is characterized by chronic intestinal inflammation. It is commonly treated with anti-inflammatory drugs, such as corticosteroids and biologics. Share on Pinterest ...

Ulcerative Colitis Market grows at 5.4% CAGR (2025–2033), reaching US$ 12.79 Billion on rising biologic adoption, biosimilars, and personalized IBD therapies. North America leads the ulcerative ...

Please provide your email address to receive an email when new articles are posted on . “We can now say with confidence, while certainly this isn’t necessarily the way most of us practice, that you ...

For women with inflammatory bowel disease (IBD), pregnancy is already high-stakes -- and conflicting medical advice worldwide has only added to the uncertainty. Now, a global team of specialists and ...